Minted: - / 5000

707 Mytatrienediol
5d66fbf650b76b0f6c8624bd026c3e706b88ae88e7869e6219d54110efc010c4

Properties

Background

Yellow
Bottle

Green
Cap

Light blue
Syringe

Purple
Bubbles
No
Drops
No
Label
Leaf

Chemistry

Formula
C20H28O3
Carbon
20
Polarity
Neutral

Mytatrienediol (developmental code name SC-6924; former tentative brand names Manvene, Anvene), also known as 16α-methyl-16β-epiestriol 3-methyl ether or 16β-hydroxy-16α-methylestradiol 3-methyl ether, is a synthetic steroidal estrogen medication and an estrogen ether which was derived from estriol and was developed for clinical use in the late 1950s but was never marketed. It was investigated as a weak and mildly estrogenic medication for men to treat atherosclerosis, improve serum lipid profiles, and reduce the risk of myocardial infarction. However, while preclinical research supported the profile of mytatriendiol as a weak estrogen, the medication was found in clinical trials to produce estrogenic side effects including feminization, breast pain, and gynecomastia in men similarly and comparably to other estrogens such as ethinylestradiol and conjugated estrogens, and its side effects ultimately precluded its use. The medication was also studied to treat bone pain in patients with multiple myeloma, metastatic bone disease, and osteoporosis, with effectiveness seen.

From Wikipedia, the free encyclopedia. License: CC BY-SA.